The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
Open accessAbstract
Cytochrome P450 3A4 (CYP3A4) metabolizes ∼50% of all clinically used drugs. Although CYP3A4 expression varies widely between individuals, the contribution of genetic factors remains uncertain. In this study, we measured allelic CYP3A4 heteronuclear RNA (hnRNA) and mRNA expression in 76 human liver samples heterozygous for at least one of eight marker SNPs and found marked allelic expression imbalance (1.6–6.3-fold) in 10/76 liver samples (13%). This was fully accounted for by an intron 6 SNP (rs35599367, C>T), which also affected mRNA expression in cell culture on minigene transfections. CYP3A4 mRNA level and enzyme activity in livers with CC genotype were 1.7- and 2.5-fold, respectively, greater than in CT and TT carriers. In 235 patients taking stable doses of atorvastatin, simvastatin, or lovastatin for lipid control, carriers of the T allele required significantly lower statin doses (0.2–0.6-fold, P=0.019) than non-T carriers for optimal lipid control. These results indicate that intron 6 SNP rs35599367 markedly affects expression of CYP3A4 and could serve as a biomarker for predicting response to CYP3A4-metabolized drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,330
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Self-citationGrundy, S. M., Cleeman, J. I., Bairey Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.001 · Cited by 1,550
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Genetic contribution to variable human CYP3A-mediated metabolism
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 990
The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans
P.B. Danielson, B. S. P. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337054 · Cited by 772
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
Sex Is A Major Determinant of Cyp3a4 Expression in Human Liver
Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2003) · Hepatology · doi:10.1002/hep.1840380424 · Cited by 529
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L., & Sadée, W. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000178311.02878.83 · Cited by 490
Self-citationAmirimani, B., Walker, A. H., Weber, B. L., & Rebbeck, T. R. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.18.1588 · Cited by 465
Neuvonen, P. J., Kantola, T., & Kivistö, K. T. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90165-5 · Cited by 406
Özdemir, V., KALOW, W., Tang, B.-K., Paterson, A. D., Walker, S. E., Endrényi, L., & Kashuba, A. D. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200007000-00001 · Cited by 398
Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4
Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., & Malkowicz, S. B. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1225 · Cited by 360
CYP3A Variation and the Evolution of Salt-Sensitivity Variants
Thompson, E. E., Kuttab-Boulos, H., Witonsky, D., Yang, L., Roe, B. A., & Di Rienzo, A. (2004) · The American Journal of Human Genetics · doi:10.1086/426406 · Cited by 331
Regulation of CYP3A Gene Transcription by the Pregnane X Receptor
Goodwin, B., Redinbo, M. R., & Kliewer, S. A. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.111901.111051 · Cited by 327
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
Lamba, J. K., Lin, Y. S., Thummel, K., Daly, A., Watkins, P. B., Strom, S., Zhang, J., & Schuetz, E. G. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00006 · Cited by 316
Westlind, A., Löfberg, L., Tindberg, N., Andersson, T. B., & Ingelman-Sundberg, M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0752 · Cited by 300
Takagi, S., Nakajima, M., Mohri, T., & Yokoi, T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709382200 · Cited by 278
The Splicing Factor SF2/ASF Regulates Translation Initiation by Enhancing Phosphorylation of 4E-BP1
Michlewski, G., Sanford, J. R., & Cáceres, J. F. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.013 · Cited by 277
MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting
Pan, Y.-Z., Gao, W., & Yu, A.-M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027680 · Cited by 272
Westlind-Johnsson, A., Malmebo, S., Johansson, A., Otter, C., Andersson, T. B., Johansson, I., Edwards, R. J., Boobis, A. R., & Ingelman-Sundberg, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.755 · Cited by 258
Ball, S. E., Scatina, J., Kao, J., Ferron, G. M., Fruncillo, R., Mayer, P., Weinryb, I., Guida, M., Hopkins, P. J., Warner, N., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70037-8 · Cited by 233
FIEGENBAUM, M., DASILVEIRA, F., VANDERSAND, C., VANDERSAND, L., FERREIRA, M., PIRES, R., & HUTZ, M. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.003 · Cited by 216
Wang, D., Chen, H., Momary, K. M., Cavallari, L. H., Johnson, J. A., & Sadée, W. (2008) · Blood · doi:10.1182/blood-2008-03-144899 · Cited by 215
Self-citationGrabczyk, E. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.14.2815 · Cited by 203
Lipid-lowering response to statins is affected by CYP3A5 polymorphism
Kivistö, K. T., Niemi, M., Schaeffeler, E., Pitkälä, K., Tilvis, R., Fromm, M. F., Schwab, M., Eichelbaum, M., & Strandberg, T. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114762.78957.a5 · Cited by 193
Buratti, E., Brindisi, A., Pagani, F., & Baralle, F. E. (2004) · The American Journal of Human Genetics · doi:10.1086/420978 · Cited by 188
Lemaire, R., Prasad, J., Kashima, T., Gustafson, J., Manley, J. L., & Lafyatis, R. (2002) · Genes & Development · doi:10.1101/gad.939502 · Cited by 162
CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity
García‐Martín, E., Martínez, C., Pizarro, R. M., Garcia-Gamito, F. J., Gullstén, H., Raunio, H., & Agúndez, J. A. G. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121371 · Cited by 136
Variability of CYP3A7 expression in human fetal liver
Leeder, J. S., Gaedigk, R., Marcucci, K. A., Gaedigk, A., Vyhlidal, C. A., Schindel, B. P., & Pearce, R. E. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086504 · Cited by 136
Lamba, J. K., Lamba, V., Strom, S. C., Venkataramanan, R., & Schuetz, E. G. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016600 · Cited by 136
Spurdle, A. B., Goodwin, B. J., Hodgson, E., Hopper, J. L., Chen, X., Purdie, D. M., McCredie, M. R. E., Giles, G. G., Chenevix‐Trench, G., & Liddle, C. (2002) · Pharmacogenetics · doi:10.1097/00008571-200207000-00003 · Cited by 135
Lamba, J. K., Lamba, V., & Schuetz, E. G. (2005) · Current Drug Metabolism · doi:10.2174/1389200054633880 · Cited by 132
Itraconazole greatly increases plasma concentrations and effects of felodipine
Jalava, K.-M., Olkkola, K. T., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90191-0 · Cited by 127
Single Nucleotide Polymorphism Genotyping Using Allele-Specific PCR and Fluorescence Melting Curves
Papp, A. C., Pinsonneault, J. K., Cooke, G. E., & Sadée, W. (2003) · BioTechniques · doi:10.2144/03345dd03 · Cited by 124
Self-citationZeigler-Johnson, C. M., Friebel, T. M., Walker, A. H., Wang, Y., Spangler, E., Panossian, S., Patacsil‐Coomes, M., Aplenc, R., Wein, A. J., Malkowicz, S. B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1651 · Cited by 123
Clinical implications ofCYP3Apolymorphisms
Wojnowski, L., & Kamdem, L. K. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.2.171 · Cited by 114
Rodríguez‐Antona, C., Sayi, J., Gustafsson, L. L., Bertilsson, L., & Ingelman‐Sundberg, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.020 · Cited by 111
Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin
Park, J.-E., Kim, K.-B., Bae, S. K., Moon, B., Liu, K., & Shin, J. (2008) · Xenobiotica · doi:10.1080/00498250802334391 · Cited by 110
Kajinami, K., Brousseau, M. E., Ordovás, J. M., & Schaefer, E. J. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.078 · Cited by 109
Gao, Y. Z., Zhang, L., & Fu, Q. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0502-x · Cited by 91
Association Between Nonalcoholic Hepatic Steatosis and Hepatic Cytochrome P-450 3A Activity
Kolwankar, D., Vuppalanchi, R., Ethell, B. T., Jones, D. R., Wrighton, S. A., Hall, S. D., & Chalasani, N. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.12.021 · Cited by 91
Self-citationIdentification of a Novel Polymorphic Enhancer of the Human CYP3A4 Gene
Matsumura, K., Saito, T., Takahashi, Y., Ozeki, T., Kiyotani, K., Fujieda, M., Yamazaki, H., Kunitoh, H., & Kamataki, T. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.2.326 · Cited by 91
Genetic Variants of the Human H+/Dipeptide Transporter PEPT2: Analysis of Haplotype Functions
Pinsonneault, J. K., Nielsen, C. U., & Sadée, W. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073098 · Cited by 85
Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers
Hugo, H. J., Cures, A., Suraweera, N., Drabsch, Y., Purcell, D., Mantamadiotis, T., Phillips, W. A., Dobrovic, A., Zupi, G., Gonda, T. J., et al. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20378 · Cited by 84
NUCLEAR RECEPTOR EXPRESSION IN FETAL AND PEDIATRIC LIVER: CORRELATION WITH CYP3A EXPRESSION
Vyhlidal, C. A., Gaedigk, R., & Leeder, J. S. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005967 · Cited by 72
Sex-Dependent Genetic Markers of CYP3A4 Expression and Activity in Human Liver Microsomes
Schirmer, M., Rosenberger, A., Klein, K., Kulle, B., Toliat, M. R., Nürnberg, P., Zanger, U. M., & Wojnowski, L. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.5.443 · Cited by 70
Association of genotypes of the CYP3A cluster with midazolam disposition in vivo
Miao, J., Jin, Y., Marunde, R. L., Kim, S., Quinney, S. K., Radovich, M., Li, L., & Hall, S. D. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.21 · Cited by 66
Willrich, M. A. V., Hirata, M. H., Genvigir, F. D. V., Arazi, S. S., Rebecchi, I. M. M., Rodrigues, A. C., Bernik, M. M. S., Dórea, E. L., Bertolami, M. C., Faludi, A. Á., et al. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.07.032 · Cited by 65
Becker, M. L., Visser, L. E., van Schaik, R. H. N., Albert Hofman, D., Uitterlinden, A. G., & Stricker, B. H. C. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1866 · Cited by 57
Influence of Friedreich Ataxia GAA Noncoding Repeat Expansions on Pre-mRNA Processing
Baralle, M., Pastor, T., Bussani, E., & Pagani, F. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.018 · Cited by 54
Statin Regulation of CYP3A4 and CYP3A5 Expression
Willrich, M. A. V., Hirata, M. H., & Hirata, R. D. C. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.42 · Cited by 52
Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status
Hirota, T., Ieiri, I., Takane, H., Maegawa, S., Hosokawa, M., Kobayashi, K., Chiba, K., Nanba, E., Oshimura, M., Satō, T., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh313 · Cited by 51
Genotyping panel for assessing response to cancer chemotherapy
Dai, Z., Papp, A. C., Wang, D., Hampel, H., & Sadée, W. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-24 · Cited by 26
Self-citationPrediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans
Perera, M. A., Thirumaran, R. K., Cox, N. J., Hanauer, S. B., Das, S., Brimer, C., Lamba, V., Schuetz, E. G., Ratain, M. J., & Rienzo, A. D. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.13 · Cited by 22
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, M., van Gelder, T., Åsberg, A., Haufroid, V., Hesselink, D. A., Langman, L., Lemaitre, F., Marquet, P., Seger, C., Shipkova, M., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000640 · Cited by 707
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Cytochrome P450 variations in different ethnic populations
McGraw, J., & Waller, D. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.657626 · Cited by 286
Metadata
- Authors
- Wang, D., Guo, Y., Wrighton, S. A., Cooke, G. E., & Sadee, W.
- Venue
- The Pharmacogenomics Journal
- Published
- 2010-04-13
- Volume
- 11
- Issue
- 4
- Pages
- 274-286
- ISSN
- 1470-269X (ISSN-L)
- 1473-1150
- OpenAlex
- W2080228333
- Cited by
- 505
- References
- 57
- FWCI
- 31.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.